GlassScriptPhysician profile
Darith S Khay
NPI 1295761609
$5,225.63
in general payments reported to CMS, 2019-2025
23 companies · $795 in 2025
The $795 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,688 · 2020: $132 · 2021: $800 · 2022: $556 · 2023: $1,117 · 2024: $138 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $894.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $593.33 | 2019-2025 | Arexvy, Penmenvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $538.04 | 2019-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.04 | 2019-2025 | |
| Abbvie INC. | $355.03 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $249.82 | 2019 | |
| Paratek Pharmaceuticals, INC. | $231.68 | 2021-2022 | |
| Si-Bone, INC. | $150.34 | 2023 | |
| Janssen Scientific Affairs, LLC | $146.13 | 2023 | Xarelto |
| Amgen INC. | $143.64 | 2025 | Krystexxa, Repatha |
| Ibsa Pharma INC. | $138.42 | 2023 | Tirosint, Tirosint, Licart |
| Agios Pharmaceuticals, INC. | $136.39 | 2025 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $132.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.03 | 2022 | |
| Lilly USA, LLC | $124.99 | 2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Merck Sharp & Dohme LLC | $123.69 | 2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Novo Nordisk INC | $117.37 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $110.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.79 | 2022 | |
| Intuitive Surgical, INC. | $94.59 | 2023 | Da Vinci Surgical System |
| Dexcom, INC. | $41.73 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $19.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darith Khay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.